ERBB2 and non-small cell lung carcinoma: Potentially actionable target molecules have been identified in 69% of patients with advanced non-small-cell lung cancer (NSCLC), and mutations in the epidermal growth factor receptor (EGFR) gene are the most common, followed by KRAS, ALK (Anaplastic lymphoma kinase), MET (mesenchymal–epithelial transition), HER2, ROS1 (ROS proto-oncogene 1), BRAF (V-raf murine sarcoma viral oncogene homolog B), RET (Rearranged during Transfection), etc. [3].